If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
=== Liquid injection === The recently developed liquid injection FD ionization (LIFDI) technique "presents a major breakthrough for FD-MS of reactive analytes": Transition metal complexes are neutral and due to their reactivity, do not undergo protonation or ion attachment. They benefit from both: the soft FD ionization and the safe and simple LIFDI transfer of air/moisture sensitive analyte solution. This transfer occurs from the Schlenk flask to the FD emitter in the ion source through a fused silica capillary without breaking the vacuum. LIFDI has been successfully coupled to a Fourier transform ion cyclotron resonance (FTICR) mass spectrometer. The coupled system enables analysis of sulphur-containing materials in crude oil under extremely high mass resolving power conditions.
=== Dispute with Vivendi === On September 20, 2004, GameSpot reported that Sierra's parent company, Vivendi Universal Games, was in a legal battle with Valve over the distribution of Half-Life 2 to cyber cafés. Cyber cafés were important for the gaming market in Asia, where PC and broadband penetration per capita were much lower in most territories. According to Vivendi, the distribution contract they signed with Valve included cyber cafés. This would mean that only Vivendi could distribute Half-Life 2 to cyber cafés — not Valve through the Steam system. On November 29, 2004, Judge Thomas S. Zilly, of U.S. Federal District Court in Seattle, Washington, ruled that Vivendi and its affiliates were not authorized to distribute (directly or indirectly) Valve games through cyber cafés for pay-to-play activities according to the parties' current publishing agreement. Zilly also ruled in favor of the Valve motion regarding the contractual limitation of liability, allowing Valve to recover copyright damages for any infringement as allowed by law without regard to the publishing agreement's limitation of liability clause. On April 29, 2005, Valve and Vivendi announced a settlement. Vivendi would cease distributing all retail packaged versions of Valve games by August 31, 2005. Vivendi was also to notify distributors and cyber cafés that had been licensed by Vivendi that only Valve had the authority to distribute cyber café licenses; their licenses were revoked and switched to Valve's.
In general, ERs and progesterone receptors (PRs) are gene activators, with increased mRNA and subsequent protein synthesis following hormone exposure. Male and female brains differ in the distribution of estrogen receptors; this is widely assumed to be caused by neonatal estradiol exposure, with some mechanisms being proven, however the complete underlying mechanism remains uncertain. Estrogen and progesterone receptors show differential expression where they are found in neurons of the anterior and mediobasal hypothalamus, notably:
==== The Scout Association (United Kingdom) ==== The Scout Association refers to WOSM's emblem as its "Membership Award" and uses it as its joining badge for its Beavers, Cubs, Scouts, Explorer Scouts and Scout Network, with progressing requirements intended to help the member understand their commitment.
Sources: en.wikipedia.org
A darknet market is a commercial website on the dark web that operates via darknets such as Tor and I2P. They function primarily as black markets, selling or brokering transactions involving drugs, cyber-arms, weapons, counterfeit currency, stolen credit card details, forged documents, unlicensed pharmaceuticals, steroids, and other illicit goods as well as the sale of legal products. In December 2014, a study by Gareth Owen from the University of Portsmouth suggested the second most popular sites on Tor were darknet markets. Following on from the model developed by Silk Road, contemporary markets are characterized by their use of darknet anonymized access (typically Tor), Bitcoin or Monero payment with escrow services, and eBay-like vendor feedback systems.
=== Waste water treatment === Thanks to the easy separation by applying a magnetic field and the very large surface to volume ratio, magnetic nanoparticles have a potential for treatment of contaminated water. In this method, attachment of EDTA-like chelators to carbon coated metal nanomagnets results in a magnetic reagent for the rapid removal of heavy metals from solutions or contaminated water by three orders of magnitude to concentrations as low as micrograms per Litre. Magnetic nanobeads or nanoparticle clusters composed of FDA-approved oxide superparamagnetic nanoparticles (e.g. maghemite, magnetite) hold much potential for waste water treatment since they express excellent biocompatibility which concerning the environmental impacts of the material is an advantage compared to metallic nanoparticles.
=== Pain === Methadone is used as an analgesic in chronic pain, often in rotation with other opioids. Due to its activity at the NMDA receptor, it may be more effective against neuropathic pain; for the same reason, tolerance to the analgesic effects may be less than that of other opioids.
An example daily menu can consist of: Breakfast: curds and nuts, mashed potatoes with nuts, apple-quince chip sticks, sugarless coffee, and vitamins Lunch: jellied pike perch, borscht with meat, goulash with buckwheat, bread, black currant juice, sugarless tea Supper: rice and meat, broccoli and cheese, nuts, tea with sugar Second supper: dried beef, cashew nuts, peaches, grape juice Sweden: Swedish astronaut Christer Fuglesang was not allowed to bring reindeer jerky with him on board a shuttle mission as it was "weird" for the Americans so soon before Christmas. He had to go with moose instead. France: In April 2021 French astronaut Thomas Pesquet brought with him on SpaceX Crew-2 a few signature French dishes to share with his fellow astronauts: space safe version of beef bourguignon, einkorn risotto, and crêpe Suzette. Poland: Specially for IGNIS, the first Polish mission to the International Space Station, scheduled for spring 2025 and featuring ESA project astronaut Dr. Sławosz Uznański-Wiśniewski, the commercial company LYOFOOD, in collaboration with the European Space Agency, developed a Bonus Food menu of freeze-dried signature Polish meals. The menu includes pierogi stuffed with cabbage and mushrooms, tomato soup with noodles, Polish “leczo” stew with buckwheat, and apple crumble for dessert. The recipes for the first three dishes were developed by renowned Polish chef and restaurateur Mateusz Gessler, while the apple crumble was selected from LYOFOOD’s dessert offerings. Usually, freeze-dried food rehydrates by absorbing added water.
Ken Levine and other members of Looking Glass Studios founded Irrational Games in 1997. Their first game was System Shock 2, a sequel to Looking Glass's System Shock, and was a critical, but not commercial, success. Levine had attempted to pitch a sequel to System Shock 2 to Electronic Arts, but the publisher rejected the idea based on System Shock 2's disappointing sales. Irrational developed other games, including Freedom Force, Tribes: Vengeance, the canceled title Deep Cover, and The Lost which was never released due to legal complications. The wanted to return to a more free-form game with strong narrative in the same style as System Shock 2, feeling there was more to do with some of the concept of that game. At the same time, they were mindful of making a successor that was more accessible to a wider variety of players. "We recognized that there were things in System Shock 2 that were holding it back, that were excessively complicated, that were opaque or hard for people to understand or that they simply didn't like," Irrational co-founder Jonathan Chey recalled. By 2002, the team had come up with a core gameplay mechanic based on three groups: drones that would carry a desirable resource, protectors that would guard the drones, and harvesters that would attempt to take the resource from the drones. These groups would eventually become the Little Sisters, Big Daddies, and Splicers in the final game. They began working on a setting to pitch the idea to publishers. A 2002 demonstration version was based on the Unreal Engine 2 for the Xbox.
Sources: en.wikipedia.org
Although clinical psychologists and psychiatrists can be said to share a same fundamental aim—the alleviation of mental distress—their training, outlook, and methodologies are often quite different. Perhaps the most significant difference is that psychiatrists are licensed physicians. As such, psychiatrists often use the medical model to assess psychological problems (i.e., those they treat are seen as patients with an illness) and can use psychotropic medications as a method of addressing the illness—although some also employ psychotherapy as well. Psychiatrists are able to conduct physical examinations, order and interpret laboratory tests and EEGs, and may order brain imaging studies such as computed tomography (CT or CAT), MRI, and PET scanning. Conversely, clinical psychologists conduct specialist assessment and psychometric testing. Such assessments and tests would not normally only be administered and interpreted by psychologists due to their advanced training in psychometric assessment. Standard clinical psychologists also usually possess more advanced training and specialist knowledge in psychosocial development and psychological therapies. Clinical psychologists generally do not prescribe medication, although there is a movement for psychologists to have prescribing privileges. These medical privileges require additional training and education.
=== Opioid overdose and/or opioid use disorder === Methocinnamox is able to reverse the respiratory depressant effects of fentanyl and heroin in animals. However, unlike naloxone, another opioid antagonist, its action lasts around 2 weeks if administered subcutaneously and up to 5 days if administered intravenously. This could make it a better antidote than naloxone in opioid overdoses, because naloxone usually lasts around 30 minutes, there is a need for repeated administration and a danger of renarcotization. By acting longer, methocinnamox prevents these dangers. Methocinnamox has not yet been tested in humans as of 2022. However, it has been tested in rodents and monkeys. It was reported in March 2020 that clinical trials of methocinnamox were expected to begin within 18 to 24 months. In March 2023, it was reported that a phase 1 clinical trial of methocinnamox funded by the National Institutes of Health (NIH) would possibly start in 2024.
Donepezil: Donepezil is a widely used acetylcholinesterase inhibitor indicated for Alzheimer's disease. The drug can be administered orally or with a transdermal patch. However, the estimated time to peak will differ between both routes of administration. Oral donepezil has a peak concentration time of 3 to 8 hours depending on the dosage, while transdermal donepezil has an expected time to peak at 7 days.
Hemoglobin concentration measurement is among the most commonly performed blood tests, usually as part of a complete blood count. For example, it is typically tested before or after blood donation. Results are reported in g/L, g/dL or mol/L. 1 g/dL equals about 0.6206 mmol/L, although the latter units are not used as often due to uncertainty regarding the polymeric state of the molecule. This conversion factor, using the single globin unit molecular weight of 16,000 Da, is more common for hemoglobin concentration in blood. For MCHC (mean corpuscular hemoglobin concentration) the conversion factor 0.155, which uses the tetramer weight of 64,500 Da, is more common. Normal levels are:
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.